{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T17:06:45Z","timestamp":1767978405240,"version":"3.49.0"},"reference-count":88,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,18]],"date-time":"2013-07-18T00:00:00Z","timestamp":1374105600000},"content-version":"vor","delay-in-days":1447,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1016\/j.rmed.2009.03.008","type":"journal-article","created":{"date-parts":[[2009,4,11]],"date-time":"2009-04-11T04:20:12Z","timestamp":1239423612000},"page":"1098-1113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":97,"title":["The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update"],"prefix":"10.1016","volume":"103","author":[{"given":"Stephen","family":"Holgate","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Buhl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Bousquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoya","family":"Panahloo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2009.03.008_bib1","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003559.pub3","article-title":"Anti-IgE for chronic asthma in adults and children","author":"Walker","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rmed.2009.03.008_bib2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1080\/02770900802085485","article-title":"Asthma 2008: targeting immunoglobulin E to achieve disease control","volume":"45","author":"Prenner","year":"2008","journal-title":"J Asthma"},{"key":"10.1016\/j.rmed.2009.03.008_bib3","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3132\/pcrj.2008.00031","article-title":"The use of omalizumab in asthma","volume":"17","author":"Price","year":"2008","journal-title":"Prim Care Respir J"},{"key":"10.1016\/j.rmed.2009.03.008_bib4","doi-asserted-by":"crossref","unstructured":"Corren J, Casale TB, Lanier B, Buhl R, Holgate S, Jimenez P. Safety and tolerability of omalizumab. Clin Exp Allergy, in press. doi: 10.1111\/j.1365-2222.2009.03214.x.","DOI":"10.1111\/j.1365-2222.2009.03214.x"},{"key":"10.1016\/j.rmed.2009.03.008_bib5","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jaci.2004.11.053","article-title":"The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation","volume":"115","author":"Holgate","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmed.2009.03.008_bib6","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/j.1398-9995.2008.01723.x","article-title":"An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma","volume":"63","author":"Sullivan","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/j.rmed.2009.03.008_bib7","unstructured":"Global Initiative for Asthma. Global strategy for asthma management and prevention. Issued January 1995 (NIH Publication No. 02-3659); updated 2002, 2003, 2004, 2005, 2006, 2007. Available at: www.ginasthma.org."},{"key":"10.1016\/j.rmed.2009.03.008_bib8","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1164\/ajrccm.162.6.ats9-00","article-title":"Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions","volume":"162","author":"American Thoracic Society","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2009.03.008_bib9","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1164\/rccm.200401-033OC","article-title":"Can guideline-defined asthma control be achieved? The gaining optimal asthma control study","volume":"170","author":"Bateman","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"Abstracts issue","key":"10.1016\/j.rmed.2009.03.008_bib10","first-page":"A613","article-title":"Characteristics of omalizumab-treated patients in the EXCELS study","volume":"177","author":"Fish","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2009.03.008_bib11","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S1081-1206(10)61707-3","article-title":"Design and baseline characteristics of the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma","volume":"92","author":"Dolan","year":"2004","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.rmed.2009.03.008_bib12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1136\/thx.54.4.301","article-title":"Risk factors for death from asthma, chronic obstructive pulmonary disease, and cardiovascular disease after a hospital admission for asthma","volume":"54","author":"Guite","year":"1999","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2009.03.008_bib13","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S1081-1206(10)62083-2","article-title":"Risk factors for recurrent asthma hospital visits and death among a population of indigent older adults with asthma","volume":"89","author":"Hartert","year":"2002","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.rmed.2009.03.008_bib14","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3109\/02770909809048968","article-title":"Features that distinguish those who die from asthma from community controls with asthma","volume":"35","author":"Tough","year":"1998","journal-title":"J Asthma"},{"key":"10.1016\/j.rmed.2009.03.008_bib15","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1183\/09031936.04.00064204","article-title":"Relationship between quality of life and clinical status in asthma: a factor analysis","volume":"23","author":"Juniper","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2009.03.008_bib16","doi-asserted-by":"crossref","first-page":"A32","DOI":"10.1016\/S1098-3015(10)67236-1","article-title":"The human impact of severe persistent allergic asthma; results of a multinational study","volume":"8","author":"Turk","year":"2005","journal-title":"Value Health"},{"key":"10.1016\/j.rmed.2009.03.008_bib17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1183\/09031936.02.00232001","article-title":"Costs of asthma are correlated with severity: a 1-yr prospective study","volume":"19","author":"Godard","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2009.03.008_bib18","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1183\/09031936.04.00004904","article-title":"Asthma severity and medical resource utilisation","volume":"23","author":"Antonicelli","year":"2004","journal-title":"Eur Respir J"},{"issue":"Suppl. II","key":"10.1016\/j.rmed.2009.03.008_bib19","first-page":"P21","article-title":"The economic and human impact of poor control in patients with severe persistent allergic asthma: results from a multinational study","volume":"60","author":"Turk","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2009.03.008_bib20","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1183\/09031936.98.12061322","article-title":"Costs of asthma according to the degree of severity","volume":"12","author":"Serra-Battles","year":"1998","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2009.03.008_bib21","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1183\/09031936.03.00261903","article-title":"The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma","volume":"22","author":"ENFUMOSA","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2009.03.008_bib22","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nri2275","article-title":"Dendritic cells and epithelial cells: linking innate and adaptive immunity in asthma","volume":"8","author":"Hammad","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.rmed.2009.03.008_bib23","doi-asserted-by":"crossref","first-page":"S486","DOI":"10.1067\/mai.2003.120","article-title":"IgE, mast cells, basophils, and eosinophils","volume":"111","author":"Prussin","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmed.2009.03.008_bib24","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1067\/mai.2003.1595","article-title":"Allergic and nonallergic forms of atopic diseases","volume":"112","author":"Novak","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmed.2009.03.008_bib25","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1165\/ajrcmb.20.1.3255","article-title":"B7 costimulation is required for IL-5 and IL-13 secretion by bronchial biopsy tissue of atopic asthmatic subjects in response to allergen stimulation","volume":"20","author":"Jaffar","year":"1999","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.rmed.2009.03.008_bib26","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1164\/rccm.200312-1651OC","article-title":"Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma","volume":"170","author":"Djukanovi\u0107","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2009.03.008_bib27","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.4049\/jimmunol.158.3.1438","article-title":"Down-regulation of Fc(\u025b)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody","volume":"158","author":"MacGlashan","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.rmed.2009.03.008_bib28","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nri2273","article-title":"IgE in allergy and asthma today","volume":"8","author":"Gould","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.rmed.2009.03.008_bib29","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jaci.2003.11.044","article-title":"Omalizumab rapidly decreases nasal allergic response and Fc\u025bRI on basophils","volume":"113","author":"Lin","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmed.2009.03.008_bib30","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1126\/science.1100283","article-title":"A critical role for eosinophils in allergic airways remodeling","volume":"305","author":"Humbles","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.rmed.2009.03.008_bib31","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1126\/science.1099472","article-title":"Defining a link with asthma in mice congenitally deficient in eosinophils","volume":"305","author":"Lee","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.rmed.2009.03.008_bib32","doi-asserted-by":"crossref","first-page":"26368","DOI":"10.1016\/S0021-9258(18)47203-1","article-title":"The binding site on human immunoglobulin E for its high affinity receptor","volume":"269","author":"Presta","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.rmed.2009.03.008_bib33","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1159\/000237010","article-title":"Inhibition of allergic reactions with antibodies to IgE","volume":"107","author":"Shields","year":"1995","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.rmed.2009.03.008_bib34","unstructured":"Genentech Inc. Omalizumab (Xolair\u00ae) full prescribing information, July 2007. Available at: http:\/\/www.gene.com\/gene\/products\/information\/immunological\/xolair\/insert.jsp. Accessed 02 June 2008."},{"key":"10.1016\/j.rmed.2009.03.008_bib35","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1164\/ajrccm.155.6.9196083","article-title":"Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response","volume":"155","author":"Boulet","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2009.03.008_bib36","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0091-6749(97)70202-1","article-title":"Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis","volume":"100","author":"Casale","year":"1997","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmed.2009.03.008_bib37","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1067\/mai.2000.108310","article-title":"Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis","volume":"106","author":"\u00c4delroth","year":"2000","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmed.2009.03.008_bib38","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1185\/030079903125002171","article-title":"Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma","volume":"19","author":"Hochhaus","year":"2003","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.rmed.2009.03.008_bib39","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","article-title":"Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE","volume":"60","author":"Humbert","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.rmed.2009.03.008_bib40","first-page":"125","article-title":"Number needed to treat to prevent one medically significant event per year with add-on omalizumab: INNOVATE","volume":"41","author":"Humbert","year":"2006","journal-title":"EAACI Abstract Book"},{"key":"10.1016\/j.rmed.2009.03.008_bib41","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1398-9995.2004.00770.x","article-title":"The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma","volume":"60","author":"Bousquet","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.rmed.2009.03.008_bib42","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/j.jaci.2004.12.314","article-title":"Omalizumab is well tolerated in adolescent\/adult patients (>12 years) with moderate-to-severe asthma","volume":"115","author":"Corren","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmed.2009.03.008_bib43","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.jaci.2007.09.022","article-title":"Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma","volume":"120","author":"Limb","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmed.2009.03.008_bib44","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2500\/aap.2007.28.3003","article-title":"Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy","volume":"28","author":"Price","year":"2007","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.rmed.2009.03.008_bib45","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2500\/108854107781285717","article-title":"The unusual suspects: a surprise regarding reactions to omalizumab","volume":"28","author":"Lieberman","year":"2007","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.rmed.2009.03.008_bib46","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1081-1206(10)60027-0","article-title":"Systemic reaction to omalizumab","volume":"97","author":"Chipps","year":"2006","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.rmed.2009.03.008_bib47","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jaci.2007.09.032","article-title":"American Academy of Allergy, Asthma and Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis","volume":"120","author":"Cox","year":"2007","journal-title":"J Allergy Clin Immunol"},{"issue":"Suppl.","key":"10.1016\/j.rmed.2009.03.008_bib48","first-page":"S483","article-title":"The diagnosis and management of anaphylaxis: an updated practice parameter","volume":"115","author":"Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmed.2009.03.008_bib49","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jaci.2005.12.002","article-title":"Anaphylaxis, killer allergy: long-term management in the community","volume":"117","author":"Simons","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmed.2009.03.008_bib50","unstructured":"National Heart Lung and Blood Institute. Expert Panel Report 3 (EPR3): Guidelines for the diagnosis and management of asthma 2007. Available at: http:\/\/www.nhlbi.nih.gov\/guidelines\/asthma\/index.htm. Accessed 02 June 2008."},{"key":"10.1016\/j.rmed.2009.03.008_bib51","doi-asserted-by":"crossref","first-page":"10474","DOI":"10.1021\/bi00033a020","article-title":"Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE","volume":"34","author":"Liu","year":"1995","journal-title":"Biochemistry"},{"key":"10.1016\/j.rmed.2009.03.008_bib52","series-title":"Center for Biologics Evaluation and Research. BLA STN 103976\/0, briefing document on safety","author":"US Food and Drug Administration","year":"2003"},{"key":"10.1016\/j.rmed.2009.03.008_bib53","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.jaci.2007.06.038","article-title":"Severe serum sickness-like syndrome after omalizumab therapy for asthma","volume":"120","author":"Pilette","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.rmed.2009.03.008_bib54","first-page":"A359","article-title":"Clinical data do not suggest a causal relationship between omalizumab therapy and cancer","volume":"2","author":"Fern\u00e1ndez","year":"2005","journal-title":"Proc Am Thorac Soc"},{"key":"10.1016\/j.rmed.2009.03.008_bib55","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2222.2007.02650.x","article-title":"Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection","volume":"37","author":"Cruz","year":"2007","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.rmed.2009.03.008_bib56","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.rmed.2007.01.011","article-title":"Predicting and evaluating response to omalizumab in patients with severe allergic asthma","volume":"101","author":"Bousquet","year":"2007","journal-title":"Respir Med"},{"key":"10.1016\/j.rmed.2009.03.008_bib57","doi-asserted-by":"crossref","first-page":"S171","DOI":"10.1016\/j.jaci.2007.12.628","article-title":"Pre-treatment specific IgE levels are not useful in predicting a response to omalizumab therapy","volume":"121","author":"Martin","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmed.2009.03.008_bib58","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.rmed.2007.08.006","article-title":"Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France","volume":"102","author":"Molimard","year":"2008","journal-title":"Respir Med"},{"key":"10.1016\/j.rmed.2009.03.008_bib59","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1136\/thx.47.2.76","article-title":"Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials","volume":"47","author":"Juniper","year":"1992","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2009.03.008_bib60","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0895-4356(94)90036-1","article-title":"Determining a minimal important change in the disease specific quality of life questionnaire","volume":"47","author":"Juniper","year":"1994","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.rmed.2009.03.008_bib61","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jaci.2006.01.011","article-title":"Asthma Control Test: Reliability, validity, and responsiveness in patients not previously followed by asthma specialists","volume":"117","author":"Schatz","year":"2006","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.rmed.2009.03.008_bib62","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.rmed.2008.06.002","article-title":"Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study","volume":"102","author":"Niven","year":"2008","journal-title":"Respir Med"},{"key":"10.1016\/j.rmed.2009.03.008_bib63","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1398-9995.2004.00533.x","article-title":"Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma","volume":"59","author":"Ayres","year":"2004","journal-title":"Allergy"},{"issue":"Suppl. 3","key":"10.1016\/j.rmed.2009.03.008_bib64","article-title":"Development of an algorithm for the assessment of response to treatment with omalizumab","volume":"62","author":"Thomson","year":"2007","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2009.03.008_bib65","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1183\/09059180.00010404","article-title":"How to evaluate a patient's response to anti-IgE","volume":"16","author":"Holgate","year":"2007","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.rmed.2009.03.008_bib66","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1378\/chest.125.4.1378","article-title":"Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma","volume":"125","author":"Bousquet","year":"2004","journal-title":"Chest"},{"issue":"Suppl. 51","key":"10.1016\/j.rmed.2009.03.008_bib67","article-title":"Assessment of a responder identification treatment algorithm for omalizumab in a naturalistic setting","volume":"30","author":"Ayre","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2009.03.008_bib68","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1183\/09031936.02.00278102","article-title":"Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma","volume":"20","author":"Buhl","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2009.03.008_bib69","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S1081-1206(10)62170-9","article-title":"Omalizumab is effective in the long-term control of severe allergic asthma","volume":"91","author":"Lanier","year":"2003","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"Suppl.","key":"10.1016\/j.rmed.2009.03.008_bib70","article-title":"Retreatment with omalizumab, an anti-IgE monoclonal antibody, is well tolerated in patients with severe allergic asthma","volume":"58","author":"Bousquet","year":"2003","journal-title":"Allergy"},{"key":"10.1016\/j.rmed.2009.03.008_bib71","doi-asserted-by":"crossref","unstructured":"Slavin R, Ferioli C, Tannenbaum S, et\u00a0al. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing immunoglobulin-E and decreasing pharmacokinetic concentrations. J Allergy Clin Immunol 2009;123(1):107\u2013113, e3.","DOI":"10.1016\/j.jaci.2008.09.050"},{"key":"10.1016\/j.rmed.2009.03.008_bib72","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1365-2222.2004.1916.x","article-title":"Efficacy and safety\u00a0of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma","volume":"34","author":"Holgate","year":"2004","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.rmed.2009.03.008_bib73","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmed.2009.03.008_bib74","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1183\/09031936.01.00092101","article-title":"The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics","volume":"18","author":"Sol\u00e8r","year":"2001","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2009.03.008_bib75","first-page":"A358","article-title":"Add-on omalizumab therapy significantly reduces asthma exacerbations in patients with severe persistent asthma requiring maintenance oral corticosteroids: a pooled analysis","volume":"2","author":"Wenzel","year":"2005","journal-title":"Proc Am Thorac Soc"},{"key":"10.1016\/j.rmed.2009.03.008_bib76","doi-asserted-by":"crossref","first-page":"S280","DOI":"10.1016\/j.jaci.2005.12.1157","article-title":"Omalizumab reduced the need for steroid bursts in asthmatics concomitantly using leukotriene receptor antagonists (LTRAs)","volume":"117","author":"Zeldin","year":"2006","journal-title":"J Allergy Clin Immunol"},{"issue":"Abstracts issue","key":"10.1016\/j.rmed.2009.03.008_bib77","first-page":"A612","article-title":"Omalizumab\u00a0in patients with uncontrolled, severe persistent allergic (IgE-mediated) asthma in a real-life setting in Germany","volume":"177","author":"Korn","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl. 3","key":"10.1016\/j.rmed.2009.03.008_bib78","article-title":"A UK survey of oral corticosteroid use in patients treated with omalizumab","volume":"62","author":"Niven","year":"2007","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2009.03.008_bib79","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1378\/chest.129.2.466","article-title":"Incorporating anti-IgE (omalizumab) therapy into pulmonary medicine practice: practice management implications","volume":"129","author":"Marcus","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2009.03.008_bib80","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1034\/j.1398-9995.2003.00105.x","article-title":"Links between rhinitis and asthma","volume":"58","author":"Bousquet","year":"2003","journal-title":"Allergy"},{"key":"10.1016\/j.rmed.2009.03.008_bib81","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1365-2222.2005.02182.x","article-title":"Effect of concomitant diagnosis of allergic rhinitis on asthma-related health care use in adults","volume":"35","author":"Price","year":"2005","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.rmed.2009.03.008_bib82","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1001\/jama.286.23.2956","article-title":"Effect of omalizumab on symptoms of allergic rhinitis. A randomized controlled trial","volume":"286","author":"Casale","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.rmed.2009.03.008_bib83","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1398-9995.2004.00550.x","article-title":"Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR","volume":"59","author":"Vignola","year":"2004","journal-title":"Allergy"},{"key":"10.1016\/j.rmed.2009.03.008_bib84","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1365-2222.1991.tb00807.x","article-title":"Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis","volume":"21","author":"Juniper","year":"1991","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.rmed.2009.03.008_bib85","doi-asserted-by":"crossref","unstructured":"Humbert M, Boulet LP, Niven RM, Panahloo Z, Blogg M, Ayre G. Omalizumab therapy: patients who achieve greatest benefit for their asthma experience greatest benefit for rhinitis. Allergy 2009;64(1):81\u201384.","DOI":"10.1111\/j.1398-9995.2008.01846.x"},{"key":"10.1016\/j.rmed.2009.03.008_bib86","unstructured":"National Institute For Health And Clinical Excellence. Final appraisal determination omalizumab for severe persistent allergic asthma. 2007. Available from: http:\/\/guidance.nice.org.uk\/download.aspx?o = 450310. Accessed 18 September 2007."},{"key":"10.1016\/j.rmed.2009.03.008_bib87","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1111\/j.1398-9995.2007.01476.x","article-title":"CD-sens and clinical changes during withdrawal of Xolair after 6 years of treatment","volume":"62","author":"Nopp","year":"2007","journal-title":"Allergy"},{"key":"10.1016\/j.rmed.2009.03.008_bib88","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1183\/09031936.03.00017003","article-title":"Systematic assessment of difficult-to-treat asthma","volume":"22","author":"Robinson","year":"2003","journal-title":"Eur Respir J"}],"updated-by":[{"DOI":"10.1016\/j.rmed.2010.04.008","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000}}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611109000894?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611109000894?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T10:49:34Z","timestamp":1760611774000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611109000894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":88,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S0954611109000894"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2009.03.008","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2009.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}